Keryx Biopharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Keryx Biopharmaceuticals, Inc. (KERX)

Q2 2012 Earnings Call

August 8, 2012 8:30 am ET

Executives

James F. Oliviero – Chief Financial Officer

Ron Bentsur – Chief Executive Officer

Analysts

Matthew Kaplan – Ladenburg Thalmann & Co. Inc.

Jonathan Aschoff – Brean Murray Carret & Co.

Charles Duncan – JMP Securities

Michael King – Rodman & Renshaw, LLC

Luca Pancratov – Roth Capital Partners

Ed Arce – MLV & Co.

Stephen Willey – Stifel Nicolaus

Presentation



Operator

» Keryx Biopharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
» Keryx Biopharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
» Zogenix's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Greetings, and welcome to the Keryx Biopharmaceuticals’ Investor Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded (Operator Instructions).

It is now my pleasure to introduce your host, James Oliviero, Chief Financial Officer for Keryx Biopharmaceuticals. Thank you, sir. You may begin.

James F. Oliviero

Thank you. Good morning, and welcome to our conference call regarding Keryx Biopharmaceuticals’ Second Quarter 2012 Financial Results. I’m James Oliviero, Chief Financial Officer at Keryx, and I welcome you to our conference call today. Following our Safe Harbor statement, I will provide a brief overview of our financial results, and then turn the call over to Ron Bentsur, Company’s Chief Executive Officer, who will provide the business update on the Company.

Before we begin, I would like to remind everyone that various remarks that we make about our future expectations, plans and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Keryx cautions that these forward-looking statements are subject to risks and uncertainties that may cause our actual results to differ materially from those indicated.

1 2 3 Next › Last »